Clinical Trial

Rapamycin - Effects on Alzheimer's and Cognitive Health

Study acronym: REACH
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-11-09; most recent amendment 2026-06-05.
Status change: Recruiting → Active, Not Recruiting 2026-06-05
Status change: Not Yet Recruiting → Recruiting 2021-05-26
Trial Details
NCT Number NCT04629495
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: Alzheimer's Association
Conditions Mild Cognitive Impairment, Alzheimer Disease
Enrollment 40 participants
Start Date 2021-08-11
Primary Completion 2026-03-05 (estimated)
Study Completion 2027-03-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-09